Global Cancer Immunotherapy Market Set To Grow To $106.6bn By 2022

06 August 2018
Pharma

Visiongain has launched a new pharma report Global Cancer Immunotherapy Market to 2027: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer

The future of the cancer immunotherapy market looks promising, as a number of new and innovative therapies are coming on to the market. Monoclonal antibodies (mAbs) held the largest market share. Monoclonal antibodies have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity. Due to the success of immunotherapeutics in curing cancer, research companies are now focused on the development of immunotherapeutics for cancer treatments. Demand for personalized medicine is owing to the growth of therapeutic antibodies.

The lead analyst of the report commented - “The global cancer immunotherapy market will see strong growth over the forecast period. The approval of advance therapeutics is paradigm shifting in the field from conventional chemotherapies to immunotherapies. Increased R&D funding coupled with rising prevalence of cancer and continued commitment by government bodies and healthcare providers will propel demand and accentuate growth in the market. However, challenges in clinical trials, high costs and changes in reimbursement policies will restrain the market.
Asia Pacific is expected to experience the fastest growth as more multinational companies such as AstraZeneca, Merck and Co. and Pfizer invest in the region through mergers and acquisitions to retain their market share and thus diversify their product portfolio.’’

Leading companies featured in the report include Roche AstraZeneca, Merck & Co., Novartis, Adaxis Inc, Bristol-Myers Squibb (BMS), Bayer AG, Roche, Eli Lilly and Co. and Medtronic Plc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever